Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Breast Cancer Research

Volumn 15, Issue 5, 2013, Pages

  Dent, Rebecca A ^a,b   Lindeman, Geoffrey J ^c   Clemons, Mark ^d   Wildiers, Hans ^e   Chan, Arlene ^f   McCarthy, Nicole J ^g   Singer, Christian F ^h   Lowe, Elizabeth S ⁱ   Watkins, Claire L ⁱ   Carmichael, James ^i,j  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f Mount Hospital   (Australia)

^g WESLEY HOSPITAL   (Australia)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ ASTRAZENECA   (United Kingdom)

^j Celgene   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; OLAPARIB; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADULT; ALOPECIA; ANEMIA; APHASIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HERPES ZOSTER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MASTITIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPTIMAL DRUG DOSE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VOMITING; AGED; COHORT ANALYSIS; DRUG ANTAGONISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84884509017     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3484     Document Type: Article

References (31)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948. 10.1056/NEJMra1001389, 21067385.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
3. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19:264-271. 10.1038/modpathol.3800528, 16341146.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
5. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277. 10.1200/JCO.2009.25.9820, 20498394.
6. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357:1496-1506. 10.1056/NEJMoa071167, 17928597.
7. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodriguez CA, Crespo C, Abad M, Dominguez S, Florian J, Llorca C, Mendez M, Godes M, Cubedo R, Murias A, Batista N, Garcia MJ, Caballero R, de Alava E. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010, 123:149-157. 10.1007/s10549-009-0663-z, 20037779.
8. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671. 10.1056/NEJMoa0707056, 2743943, 18420499.
9. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819. 10.1038/nrc1457, 15510162.
10. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
11. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
12. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251. 10.1016/S0140-6736(10)60893-8, 20609468.
13. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244. 10.1016/S0140-6736(10)60892-6, 20609467.
14. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, MacPherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12:852-861. 10.1016/S1470-2045(11)70214-5, 21862407.
15. World Medical Association (WMA) Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects 1964, Adopted by the 18th WMA General Assembly, Helsinki, Finland, Available at: [http://www.wma.net/en/30publications/10policies/b3/index.html], World Medical Association (WMA).
16. AstraZeneca Our Global Policies: Bioethics 2011, [http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies], AstraZeneca.
17. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28:2512-2519. 10.1200/JCO.2009.26.9589, 20406929.
18. André F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 2012, 23:vi46-vi51. 10.1093/annonc/mds195, 23012302.
19. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
20. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
21. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001, 19:4216-4223.
22. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-7923. 10.1158/1078-0432.CCR-08-1223, 2652879, 19047122.
23. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 2009, 27:756-763. 10.1080/07357900802709159, 19440934.
24. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszawski JE, Doroshow JH. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011, 71:5626-5634. 10.1158/0008-5472.CAN-11-1227, 3166628, 21795476.
25. Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G. A Phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012, 18:2344-2351. 10.1158/1078-0432.CCR-11-2425, 22371451.
26. Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Rafi R, Tracy M, Winer E, Baselga J, Garber JE. Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors. In 2012 ASCO Annual Meeting Abstracts. J Clin Oncol 2012, 30:abst 1009.
27. Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Ellisen LW, Winer EP, Goss PE. A Phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. In 2010 ASCO Annual Meeting Abstracts. J Clin Oncol 2010, 28:abst 1019.
28. Lee J, Annunziata CM, Minasian LM, Zujewski J, Prindiville SA, Kotz HL, Squires J, Houston ND, Ji JJ, Yu M, Doroshow JH, Kohn EC. Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca). In 2011 ASCO Annual Meeting Abstracts. J Clin Oncol 2011, 29:abst 2520.
29. Oza AM, Cibula D, Oaknin A, Poole CJ, Mathijssen RH, Sonke GS, Colombo N, Špacek J, Vuylsteke P, Hirte HW, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Tchakov I, Friedlander M. Olaparib plus paclitaxel + carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label Phase II study. In 2012 ASCO Annual Meeting Abstracts. J Clin Oncol 2012, 30:abst 5001.
30. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012, 84:137-146. 10.1016/j.bcp.2012.03.018, 22469522.
31. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38. 10.1016/j.cell.2011.03.020, 21458666.